The Role of Microparticles as a Biomarker
| Status: | Withdrawn |
|---|---|
| Conditions: | Gastrointestinal, Hematology, Hematology, Hematology |
| Therapuetic Areas: | Gastroenterology, Hematology |
| Healthy: | No |
| Age Range: | 18 - 120 |
| Updated: | 2/21/2019 |
| Start Date: | July 2016 |
| End Date: | December 2022 |
The Role of Microparticles as a Biomarker in Distinguishing Between Thrombotic Thrombocytopenic Purpura (TTP) and Atypical Hemolytic Uremic Syndrome (aHUS)
The investigators propose to characterize MPs in aHUS and TTP both at the onset and
throughout treatment. The investigators believe that the number, size, and cell origin of MPs
will differ between these two diseases. The hypothesis is that endothelial derived MPs will
be higher in number and comprise a larger portion of the MP population in aHUS and that
platelet MPs will comprise a larger number and greater proportion of MPs in TTP. The
investigators believe that MP identity and number can be used to reliably differentiate
between aHUS and TTP at disease onset.
throughout treatment. The investigators believe that the number, size, and cell origin of MPs
will differ between these two diseases. The hypothesis is that endothelial derived MPs will
be higher in number and comprise a larger portion of the MP population in aHUS and that
platelet MPs will comprise a larger number and greater proportion of MPs in TTP. The
investigators believe that MP identity and number can be used to reliably differentiate
between aHUS and TTP at disease onset.
Inclusion Criteria:
- Patients with MAHA, TTP, and/or aHUS
Exclusion Criteria:
- Prisoners
We found this trial at
1
site
Univ of Rochester Medical Center One of the nation's top academic medical centers, the University...
Click here to add this to my saved trials
